Akil F. Jackson
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
Journal: British journal of cancer
Published: December 23, 2024
Targeting AXL cellular networks in kidney fibrosis.
Journal: Frontiers in immunology
Published: June 10, 2024
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
Journal: Frontiers in immunology
Published: March 13, 2024
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Journal: HIV clinical trials
Published: December 01, 2017
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 12, 2016
An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
Journal: Antiviral therapy
Published: September 21, 2016
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Journal: The Journal of infectious diseases
Published: June 30, 2016
The Canadian Institutes of Health Research response to antimicrobial resistance.
Journal: Canada communicable disease report = Releve des maladies transmissibles au Canada
Published: November 19, 2015
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
Journal: The Journal of antimicrobial chemotherapy
Published: July 30, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Journal: Antimicrobial agents and chemotherapy
Published: June 18, 2015
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
Journal: The Journal of infectious diseases
Published: June 18, 2015
Long-acting rilpivirine for HIV prevention.
Journal: Current opinion in HIV and AIDS
Published: June 08, 2015
Last Updated: 09/26/2026